Usana Health Sciences, Inc. · NYSE:USNA
Usana Health Sciences — Q2 2026 Earnings Presentation
11 slides from Usana Health Sciences's earnings presentation, Aug 5, 2026
Slide 1: USANA Health Sciences Reports Second Quarter 2026 Results
August 4, 2026 USANA Health Sciences Reports Second Quarter 2026 Results Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business SALT LAKE CITY--(BUSINESS WIRE)-- USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter e
Slide 2: Management commentary and Q2 2026 segment results
prior expectations and are updating our outlook accordingly. “We remain confident in USANA's strategic transformation from a single-channel direct sales business into a diversified, omnichannel health and wellness company built on consumer acquisition and loyalty. We are continuing to evolve our Bra
Slide 3: Hiya, Rise Wellness, Balance Sheet and Fiscal Year 2026 Outlook
Q2 2026 Year-Over-Year Sequentially Net Sales $28 million -17% -12% Active Monthly Subscribers 166,000 -17% -11% Rise Wellness Q2 2026 Year-Over-Year Sequentially Net Sales $3 million +40% -75% Balance Sheet The Company ended the quarter with $169 million in cash and cash equivalents and zero debt.
Slide 4: Balance sheet commentary and non-GAAP footnotes
driven in large part by improved working capital management. Financial flexibility remains important and is central to how we're investing in USANA's continued evolution from a single-channel direct sales business into a diversified, omnichannel health and wellness company." ________________________
Slide 5: Reconciliation of Net (Loss) Earnings to Adjusted EBITDA
financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP. Reconciliation of
Slide 6: Conference call information and Safe Harbor
For further information on USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcem
Slide 7: Forward-looking statement risk factors
currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk t
Slide 8: Condensed Consolidated Statements of Operations
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited) Three months ended July 4, June 28, 2026 2025 Net sales $ 223,273 $ 235,848 Cost of sales 48,339 50,184 Gross profit 174,934 185,664 Operating expenses: Bran
Slide 9: Condensed Consolidated Balance Sheets
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) As of As of July 4, January 3, 2026 2026 ASSETS Current assets Cash and cash equivalents $ 168,560 $ 158,380 Trade accounts receivable (net of allowance of $92 and $137, respectively) 3,337
Slide 10: Sales by Region
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES SALES BY REGION (in thousands) (unaudited) Quarter ended Percent change Change Currency excluding July 4, June 28, from prior Percent impact on currency 2026 2025 year change sales impact Core Nutritional: Asia Pacific Greater China $ 114,614 51.3% $ 113,
Slide 11: Investor contact and operating results as a percentage of net sales
_________________________ (1) Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resa
USANA Health Sciences — Q2 2026 Earnings Presentation on 6ix